Search Results
Jul 31, 2026, 07:47 ET AbbVie Reports Second-Quarter 2026 Financial Results
investors.abbvie.com.AbbVie announced the U.S. Food and Drug Administration (FDA) and the European Commission (EC) approved Skyrizi (risankizumab) for the treatment of children six years of age and older with
More news about: AbbVie
Jul 31, 2026, 07:00 ET Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
in small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for RAG-1C, a first-in-class saRNA drug candidate designed for the prevention and treatment of Proliferative Vitreoretinopathy
More news about: Ractigen Therapeutics
Jul 31, 2026, 07:00 ET CREATE Medicines Expands Targeted In Vivo CAR Platform Through Strategic Research Collaboration and Exclusive License Agreement with Monash University
Sciences, which is ranked #2 globally in the QS World University Rankings by Subject. MIPS is comprised of over 400 scientists engaged in research in drug discovery, design, delivery and use.For more, visit
More news about: CREATE Medicines, Inc.
Jul 31, 2026, 06:00 ET IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop
More news about: IDEAYA Biosciences, Inc.
Jul 31, 2026, 05:30 ET Best Sharps Mail-Back Solutions for Small Medical Practices (2026): Sharps Assure Recognized by Expert Consumers
pathogens. Proper sharps disposal is one component of broader workplace safety requirements within healthcare environments.The U.S. Food and Drug Administration also advises placing used sharps immediately into FDA-cleared sharps disposal containers. These containers are designed to be puncture
More news about: ExpertConsumers.org
Jul 31, 2026, 04:03 ET IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
peritoneal cancer achieving complete or partial response to platinum-based chemotherapy, and has been subsequently included in the National Reimbursement Drug List (NRDL) in December 2025. The Company is actively advancing the clinical and regulatory development of senaparib globally. Its Marketing Authorisation
More news about: IMPACT Therapeutics
Jul 31, 2026, 03:48 ET IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
peritoneal cancer achieving complete or partial response to platinum-based chemotherapy, and has been subsequently included in the National Reimbursement Drug List (NRDL) in December 2025. The Company is actively advancing the clinical and regulatory development of senaparib globally. Its Marketing Authorisation
More news about: IMPACT Therapeutics
Jul 31, 2026, 02:04 ET FIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD
Two-Year Commitment will Inspire the Next Generation of Scientific Innovators Through AI-Enabled Research in Healthcare and Drug DiscoveryHYDERABAD, India, July 31, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today
More news about: Amgen
Jul 31, 2026, 00:54 ET NIPRO CORPORATION、米国市場へHDを導入すべくELISIO™-HXのFDA510(k)クリアランスを取得
スーパーハイフラックス膜を採用した新しいミディアムカットオフ・ダイアライザにより、NIPROの拡張型血液透析への取り組みが米国の医療従事者に提供されます。 日本・大阪, 2026年7月31日 /PRNewswire/ -- NIPRO CORPORATIONは、United States Food and Drug Administration (FDA)より、ダイアライザ「ELISIO-HX」について510(k)クリアランスを取得しました。クリアランスは2026年7月28日より発効します。本クリアランスにより、米国でのHD（スーパーハイフラックス膜を用いた血液透析）の導入が可能となります。HDsは、NIPROが提唱する「拡張型血液透析（Expanded
More news about: Nipro Medical Corporation
Jul 30, 2026, 22:10 ET Apnimed Announces Pricing of Upsized Initial Public Offering
surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA. Apnimed's New Drug Application for AD109 was assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 28, 2027.Cautionary Note Regarding Forward-Looking Statements
More news about: Apnimed, Inc.
Jul 30, 2026, 16:06 ET Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in August 2026 seeking accelerated approval of selinexor in combination with ruxolitinib for the treatment
More news about: Karyopharm Therapeutics Inc.
Jul 30, 2026, 16:05 ET Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
Karyopharm will successfully commercialize XPOVIO or that any of Karyopharm's drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive
More news about: Karyopharm Therapeutics Inc.
Jul 30, 2026, 16:01 ET PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Duchenne muscular dystrophyFA: Friedreich's ataxiaFDA: US Food and Drug AdministrationGAAP: Generally Accepted Accounting PrinciplesHD: Huntington's diseaseNDA: New Drug ApplicationnmDMD: Nonsense mutation Duchenne muscular dystrophyR&D:
More news about: PTC Therapeutics, Inc.
Jul 30, 2026, 16:00 ET Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction
Under the agreement, Ashlins obtained exclusive rights to develop and commercialize certain drug products incorporating Lee's Pharm's interferon alpha-2b active pharmaceutical ingredient (API), a recombinant human type I interferon used as the active
More news about: Greenberg Traurig, LLP
Jul 30, 2026, 13:28 ET Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman
efficacy data, along with disclosures regarding communications with the FDA.Aardvark had emphasized that ARD-101 represented a "first-in-class" drug and that, "through alignment with the FDA," it started HERO patients 13 years and older, moved to dosing patients 10 years and older, and intended to
More news about: Hagens Berman Sobol Shapiro LLP
Jul 30, 2026, 13:24 ET CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash
InvestigationThe investigation focuses on disclosures that emerged on July 27, 2026, when Capricor shares plummeted roughly 40% to 64% following the U.S. Food and Drug Administration's (FDA) publication of its briefing document ahead of the advisory committee meeting for Deramiocel's biologics license application (BLA).The
More news about: Hagens Berman Sobol Shapiro LLP
Jul 30, 2026, 13:07 ET POSITIVE STELLUNGNAHME DES CHMP UNTERSTÜTZT BREITERE ANWENDUNG VON AMGENS REPATHA® VOR ERSTEM HERZINFARKT ODER SCHLAGANFALL
erweiterte die US-amerikanische Arzneimittelbehörde (U.S. Food and Drug Administration, FDA) den zugelassenen Anwendungsbereich von Repatha auf Erwachsene mit erhöhtem Risiko für schwerwiegende unerwünschte kardiovaskuläre
More news about: Amgen
Jul 30, 2026, 12:45 ET AVIS FAVORABLE DU CMUH CONCERNANT UNE UTILISATION PLUS LARGE DE REPATHA® D'AMGEN POUR REDUIRE LES RISQUES DE PREMIER INFARCTUS DU MYOCARDE OU D'AVC
pour la première fois en 2015 et a depuis été utilisé par plus de 10 millions de patients dans le monde.10 En août 2025, l'U.S. Food and Drug Administration (agence américaine des produits alimentaires et médicamenteux)
More news about: Amgen
Jul 30, 2026, 12:40 ET Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
(NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that following approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application, the company launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial
More news about: Lupin Pharmaceuticals, Inc.
Jul 30, 2026, 10:31 ET Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
AnalysisUlcerative Colitis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ulcerative colitis companies, including Oppilan Pharma, Genentech, Teva
More news about: DelveInsight Business Research, LLP
Jul 30, 2026, 10:30 ET Laboratory Freezers Market worth $5.11 billion by 2031 - Exclusive Report by MarketsandMarkets™
and pathology laboratory networks, advanced healthcare infrastructure, and strong presence of biobanks and research institutions. High investment in drug discovery, vaccine development, biologics, genomics, and cell and gene therapies generates substantial demand for refrigerators, freezers, and cryopreservation
More news about: MarketsandMarkets
Jul 30, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
joining the class action]On July 28, 2026, the U.S. Food and Drug Administration published briefing documents stating concerns about the data package that Replimune has offered to support accelerated approval for its drug RP1 (vusolimogene oderparepvec) in combination with Bristol Myers Squibb's
More news about: Pomerantz LLP
Jul 30, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsnOn Behalf of Investors of Celcuity Inc. - CELC
information about joining the class action]On July 14, 2026, Celcuity issued a press release announcing that it had secured U.S. Food and Drug Administration approval for its breast cancer therapy Revtorpyk (gedatolisib) and "anticipates commercial launch in late Q3 2026", representing a delayed
More news about: Pomerantz LLP
Jul 30, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alibaba Group Holding Limited - BABA
Alibaba had "entered a non-prosecution agreement to pay $600 million to resolve the Justice Department's allegations that they violated the Federal Food, Drug, and Cosmetic Act (FDCA) by failing to prevent merchants from selling and importing illegal pharmaceuticals, controlled substances, listed chemicals,
More news about: Pomerantz LLP
Jul 30, 2026, 10:00 ET Former University of Colorado Quarterbacks Reunite to Launch Beyond Limits Life Skills Academy to Help Local Teens
speaking, leadership development, financial literacy and budgeting, interview and career readiness, conflict resolution, personal safety awareness, drug and alcohol education, goal-setting and personal responsibility.To accomplish its goal of free tuition for all students, Beyond Limits Life Skills
More news about: Beyond Limits Life Skills Academy